Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. [electronic resource]
Producer: 20171031Description: 882-91 p. digitalISSN:- 1463-1326
- Adipose Tissue -- diagnostic imaging
- Diabetes Mellitus, Type 2 -- complications
- Exenatide
- Fatty Liver -- complications
- Female
- Glycated Hemoglobin -- metabolism
- Heart -- diagnostic imaging
- Humans
- Hypoglycemic Agents -- therapeutic use
- Liver -- diagnostic imaging
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Myocardium -- metabolism
- Obesity -- complications
- Pancreas -- diagnostic imaging
- Peptides -- therapeutic use
- Pericardium -- diagnostic imaging
- Postprandial Period
- Proton Magnetic Resonance Spectroscopy
- Treatment Outcome
- Triglycerides -- metabolism
- Venoms -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.